Reuters logo
BRIEF-Merck receives FDA approval of ISENTRESS HD for treatment of HIV-1 infection in appropriate patients
May 30, 2017 / 11:16 AM / 6 months ago

BRIEF-Merck receives FDA approval of ISENTRESS HD for treatment of HIV-1 infection in appropriate patients

May 30 (Reuters) - Merck & Co Inc:

* Merck receives FDA approval of Isentress HD (raltegravir), a new once-daily option, in combination with other antiretroviral agents, for the treatment of hiv-1 infection in appropriate patients

* Merck receives FDA approval of Isentress HD (raltegravir), a new once-daily option, in combination with other antiretroviral agents, for the treatment of hiv-1 infection in appropriate patients

* Merck & Co Inc says Merck anticipates isentress HD to be available in pharmacies in approximately four weeks

* Merck & Co Inc says price of Isentress HD will be same as Isentress twice daily Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below